$ACAC Acri Capital Acquisition Corpβs transformation into Foxx Development Holdings could unlock major gains for early investors. Explore the IoT-driven revenue potential, performance-based share incentives, and strategic positioning behind this high-upside deal. https://globalmarketbulletin.com/acri-capital-acac-foxx-merger-why-this-nasdaq-spac-could-become-one-of-2025s-most-profitable-tech-listings/
$ACAC My personal approach with Πainz Biomed is simple β I treat it as a high-conviction long-term spec with a tiny allocation, a multi-year horizon and a clear thesis built on a ~$20B+ TAM, strong CRC and pancreatic data and a ~67% gross margin platform sitting at microcap levels, and if management can convert this science into $10M, $50M or $100M+ revenue over time, even a small position today has the potential to make a very real difference in my long-term equity curve π
$ACAC keep it quiet, but something big is brewing ππ€«
OTC: GEAT β micro float, micro capβ¦ but a straight-up ROCKET π£π
π +250% yesterday on heavy volume.
Now whispers of a partnership are flying around β and it ainβt with some nobody.
Patent? β Momentum? β FOMO? π₯β
Iβm holding. Target? $1+. Not joking.
MCVT is a hidden gem among small caps: profitable, free of debt, and dilution-proof.
Financial stability is paramount for smaller companies navigating competitive and volatile markets, and being both profitable and debt-free can significantly impact their survival and growth prospects.
With this particular sector projected to expand from $2 trillion to $7 trillion, Mill City Ventures stands out as a compelling choice.
$INAQ $ACAC
$ACAC
MCVT
the ONLY low float with no dilution,share buyback, profitable, no r/s risk, no debt, no insider selling, low shares to borrow, and bottomed on the monthly.
$10+
DeSpac
Foxx Development Inc begins trading on Nasdaq today, as $FOXX after SPAC business combination with $ACAC
More Information :
https://sec.gov/Archives/edgar/data/1914023/000101376224002169/ea0210214-01.htm
